HD204 vs Zirabev (bevacizumab-bvzr)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

HD204

Developed by Intas Pharmaceuticals and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT03390686 · Phase 3 · active, not recruiting

This was a randomised, double-blind, active-controlled Phase 3 equivalence trial (625 patients randomised, per the sponsor) comparing HD204 with reference bevacizumab (Avastin), each with chemotherapy, in advanced non-squamous NSCLC. The primary endpoint was objective response rate at week 18, and the prespecified equivalence margin test succeeded (risk ratio 1.047, 95% CI 0.86 to 1.27), showing clinical equivalence with the reference product.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. The sponsor's topline release reports 625 patients randomised 1:1; the registry lists 650 enrolled.

Reported efficacy

Overall Response Rate (ORR) at Week 18 (18 weeks from randomization): SAMSON-II (NCT03390686), primary endpoint ORR at week 18: HD204 48.7% vs reference bevacizumab 46.5%; risk ratio 1.047 (95% CI 0.86-1.27), within prespecified equivalence margin (met)

Result source: NCT03390686

Zirabev (bevacizumab-bvzr)

Marketed by Pfizer

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT02364999 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial with 719 participants, using tumor response by RECIST as its primary clinical endpoint. PF-06439535 had a confirmed response rate of 45.3% versus 44.6% with European bevacizumab, and the prespecified equivalence margins were met, supporting a strong evidence grade.

Reported efficacy

Objective Response Rate (ORR) by Week 19 (25 weeks): Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89) (met)

Result source: NCT02364999

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHD204Zirabev (bevacizumab-bvzr)
PFS, median—Trial running · NCT03390686—Not reported
OS, median—Trial running · NCT03390686—Not reported
ORR—Trial running · NCT0339068645.3% vs 44.6%vs Bevacizumab-EUwk 25 · n 358NCT02364999
Duration of response, median—Trial running · NCT033906868.4 vs 6.6vs Bevacizumab-EUn 162NCT02364999

PFS, median

HD204
—Trial running · NCT03390686
Zirabev (bevacizumab-bvzr)
—Not reported

OS, median

HD204
—Trial running · NCT03390686
Zirabev (bevacizumab-bvzr)
—Not reported

ORR

HD204
—Trial running · NCT03390686
Zirabev (bevacizumab-bvzr)
45.3% vs 44.6%vs Bevacizumab-EUwk 25 · n 358NCT02364999

Duration of response, median

HD204
—Trial running · NCT03390686
Zirabev (bevacizumab-bvzr)
8.4 vs 6.6vs Bevacizumab-EUn 162NCT02364999
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

HD204
SAMSON-II (NCT03390686), primary endpoint ORR at week 18: HD204 48.7% vs reference bevacizumab 46.5%; risk ratio 1.047 (95% CI 0.86-1.27), within prespecified equivalence margin NCT03390686 · Phase 3 · design grade: strong · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. HD204: 0 of 4 rows · Zirabev (bevacizumab-bvzr): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricZirabev (bevacizumab-bvzr)
Dropout rate
46.1%
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs
—
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Serious AEs
22.8%
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs
alopecia 46.6%
anaemia 28.7%
fatigue 20.5%
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Zirabev (bevacizumab-bvzr)

ORR 45.3% (n=358) vs 44.6% (n=361) Bevacizumab-EU @ 25wk
responder rate · % of participants
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Duration of Response 8.38 vs 6.62 Bevacizumab-EU months
time to event · months
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 · converted to months from 36.3 weeks as posted
PFS 32.3% (n=358) vs 30.5% (n=361) Bevacizumab-EU @ 55wk
responder rate · % of participants
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Overall Survival 65.8% (n=358) vs 64.1% (n=361) Bevacizumab-EU @ 55wk
responder rate · % of participants
NCT02364999 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HD204's landscape · Zirabev (bevacizumab-bvzr)'s landscape